Skip to main content
Premium Trial:

Request an Annual Quote

Harvard /Brigham and Women's Picks LabVantage Sapphire for Legacy LIMS Phaseout

NEW YORK (GenomeWeb News) - LabVantage Solutions said today that the Channing Laboratory at Brigham and Women's Hospital and Harvard Medical School has licensed its Sapphire BioBanking Solution.
The Channing Laboratory is focused on the investigation of bacteriology, chronic disease epidemiology, and virology.
The lab will deploy Sapphire in its Respiratory Epidemiology Genotyping Laboratory as part of a multi-phase project to replace “significant portions” of its existing laboratory information management systems and other internally developed software packages, LabVantage said.
LabVantage said that the lab has been using in-house LIMS for genotyping research and has now chosen to switch to a commercial product for its biorepository and sample-tracking system.
"We were primarily seeking a solution for our biorepository needs, but quickly found that many of our internally built laboratory systems and process would be tied to the biorepository processes," Scott Weiss, principal investigator for the Channing Laboratory, said in a statement. "We needed a solution that would provide state-of-the-art biorepository management and that would also replace our legacy systems with standardized solutions.”

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.